Integrated transcriptomics, proteomics and metabolomics-based analysis uncover TAM2-associated glycolysis and pyruvate metabolic remodeling in pancreatic cancer

Tumor-associated macrophage 2 (TAM2) abundantly infiltrates pancreatic ductal adenocarcinoma (PAAD), and its interaction with malignant cells is involved in the regulation of tumor metabolism. In this study, we explored the metabolic heterogeneity involved in TAM2 by constructing TAM2-associated metabolic subtypes in PAAD.PAAD samples were classified into molecular subtypes with different metabolic characteristics based on a multi-omics analysis strategy. 20 PAAD tissues and 10 normal pancreatic tissues were collected for proteomic and metabolomic analyses. RNA sequencing data from the TCGA-PAAD cohort were used for transcriptomic analyses. Immunohistochemistry was used to assess TAM2 infiltration in PAAD tissues.The results of transcriptomics and immunohistochemistry showed that TAM2 infiltration levels were upregulated in PAAD and were associated with poor patient prognosis. The results of proteomics and metabolomics indicated that multiple metabolic processes were aberrantly regulated in PAAD and that this dysregulation was linked to the level of TAM2 infiltration. WGCNA confirmed pyruvate and glycolysis/gluconeogenesis as co-expressed metabolic pathways of TAM2 in PAAD. Based on transcriptomic data, we classified the PAAD samples into four TAM2-associated metabolic subtypes (quiescent, pyruvate, glycolysis/gluconeogenesis and mixed). Metabolic subtypes were each characterized in terms of clinical prognosis, tumor microenvironment, immune cell infiltration, chemotherapeutic drug sensitivity, and functional mechanisms.Our study confirmed that the metabolic remodeling of pyruvate and glycolysis/gluconeogenesis in PAAD was closely related to TAM2. Molecular subtypes based on TAM2-associated metabolic pathways provided new insights into prognosis prediction and therapy for PAAD patients.

[1]  C. Verbeke,et al.  Pancreatic stellate cell-induced gemcitabine resistance in pancreatic cancer is associated with LDHA- and MCT4-mediated enhanced glycolysis , 2023, Cancer Cell International.

[2]  Y. Bai,et al.  Extracellular vesicle-derived LINC00511 promotes glycolysis and mitochondrial oxidative phosphorylation of pancreatic cancer through macrophage polarization by microRNA-193a-3p-dependent regulation of plasminogen activator urokinase , 2022, Immunopharmacology and immunotoxicology.

[3]  E. Obermayr,et al.  Effect of short-term storage of blood samples on gene expression in lung cancer patients , 2022, Clinical chemistry and laboratory medicine.

[4]  Gang Yang,et al.  mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models. , 2022, Cancer letters.

[5]  Peiyuan Yin,et al.  Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy , 2022, Frontiers in Immunology.

[6]  C. Dang,et al.  Targeting cancer metabolism in the era of precision oncology , 2021, Nature reviews. Drug discovery.

[7]  B. Helmink,et al.  Hallmarks of response, resistance, and toxicity to immune checkpoint blockade , 2021, Cell.

[8]  Muh-Hwa Yang,et al.  Interplay of Immunometabolism and Epithelial–Mesenchymal Transition in the Tumor Microenvironment , 2021, International journal of molecular sciences.

[9]  E. Soriano,et al.  Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis , 2021, Annals of the Rheumatic Diseases.

[10]  N. Chandel,et al.  Cancer metabolism: looking forward , 2021, Nature Reviews Cancer.

[11]  Robert F. Gruener,et al.  oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data , 2021, Briefings Bioinform..

[12]  L. You,et al.  Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. , 2021, Cancer letters.

[13]  Sherine F. Elsawa,et al.  Macrophage Polarization States in the Tumor Microenvironment , 2021, International journal of molecular sciences.

[14]  J. Xia,et al.  MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights , 2021, Nucleic Acids Res..

[15]  Michael K. Wendt,et al.  Pyruvate carboxylase and cancer progression , 2021, Cancer & metabolism.

[16]  Xiang Chen,et al.  Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. , 2020, Cancer letters.

[17]  H. Zhan,et al.  Macrophages in pancreatic cancer: An immunometabolic perspective. , 2020, Cancer letters.

[18]  Russell G. Jones,et al.  Immunometabolic Interplay in the Tumor Microenvironment. , 2020, Cancer cell.

[19]  M. O'Hara,et al.  Challenges and Opportunities for Pancreatic Cancer Immunotherapy. , 2020, Cancer cell.

[20]  Angela N. Brooks,et al.  Visualizing and interpreting cancer genomics data via the Xena platform , 2020, Nature Biotechnology.

[21]  Ashish,et al.  Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis , 2020, Frontiers in Oncology.

[22]  P. Acedo,et al.  Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer , 2019, Cancers.

[23]  R. Deberardinis,et al.  Mechanisms and Implications of Metabolic Heterogeneity in Cancer. , 2019, Cell metabolism.

[24]  Gang Yang,et al.  The enhancement of glycolysis regulates pancreatic cancer metastasis , 2019, Cellular and Molecular Life Sciences.

[25]  Ho-Joon Lee,et al.  Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer , 2018, bioRxiv.

[26]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[27]  Lianyu Chen,et al.  CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. , 2018, Biochemical and biophysical research communications.

[28]  Bin Zhang,et al.  Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma , 2018, Cell Death & Disease.

[29]  D. Dhar,et al.  Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome , 2016, PloS one.

[30]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[31]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[32]  G. Cline,et al.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.

[33]  J. Geschwind,et al.  Tumor glycolysis as a target for cancer therapy: progress and prospects , 2013, Molecular Cancer.

[34]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[35]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[36]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[37]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[38]  Pornpimol Charoentong,et al.  ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..

[39]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[40]  Xuan Yang,et al.  Glycolysis in the progression of pancreatic cancer. , 2022, American journal of cancer research.

[41]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..